Molnupiravir has serious safety concerns: ICMR

So, it is not included in the national clinical protocol, the WHO has not included it, nor has the UK,” he added.

463
ICMR

Last Updated on January 8, 2022 by The Health Master

New Delhi: The antiviral drug molnupiravir, which recently got approval from the drug regulator and is being launched by several local drug makers, has serious safety concerns, and thus has not been included in the national Covid-19 clinical protocol recommended by the health ministry, the Indian Council of Medical Research (ICMR) director general, Balram Bhargava, said.

Bhargava said the Covid-19 task force has debated whether to include the drug in the Covid-19 treatment protocol but decided against it because of concerns.

“The US has approved it only based on 1,433 patients with a 3% reduction in moderate disease when given in mild cases.

However, we have to remember that this drug has major safety concerns. It can cause teratogenicity, mutagenicity , and it can also cause cartilage damage and can also be damaging to muscles, ” Bhargava said.

“More importantly, if this drug is given to a man or a woman, contraception has to be used for three months, as the child conceived during that period may have problems with teratogenic influences.

So, it is not included in the national clinical protocol, the WHO has not included it, nor has the UK,” he added.

Teratogenicity is the ability to cause defects in a developing foetus, whereas mutagenicity refers to permanent transmissible changes in the structure of genetic material of cells.

Bhargava further pointed out that there are concerns about children, pregnant and lactating women, those in reproductive age, soft tissue injury, history of infections and vaccinations when this drug is being prescribed.

Molnupiravir, originally developed by pharma company Merck, had initially claimed a 50% reduction in hospitalization or death in patients.

No Paracetamol, Painkillers recommended after Covaxin jab

Govt is expected to amend New Drugs and Clinical Trial Rules 2019

Chemists told to stock up on key medicines

Dr Reddy’s to launch anti-Covid drug Molnupiravir at Rs 35 per…

Govt to allow parallel submission of these applications for New Drugs

USFDA gives nod to Alembic Pharma for Doxycycline Hyclate tablets

DCGI directs all State Drugs Controllers to implement ONDLS portal

DTAB recommends Bar code on top 300 brands of drug products

Pharma Firm booked for Rs 1,627 Crore Loan Fraud

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner